| DVTa | PEa | OTEa | |||
---|---|---|---|---|---|---|
N/P-Yb | Rate/1,000c (95% CI) | N/P-Yb | Rate/1,000c (95% CI) | N/P-Yb | Rate/1,000c (95% CI) | |
By major STS subtype | ||||||
 Angiosarcoma (n = 184) | 14/147 | 95.4 (52.1, 160.0) | <11 | 26.5 (7.2, 68.0) | <11 | 39.8 (14.6, 86.6) |
 Fibrosarcoma (n = 64) | <11 | 72.1 (19.6, 184.5) | 0 | 0 | <11 | 17.6 (0.4, 97.8) |
 GIST (n = 845) | 94/683 | 137.6 (111.2, 168.4) | 33/721 | 45.7 (31.5, 64.2) | 23/730 | 31.5 (20.0, 47.3) |
 Leiomyosarcoma (n = 264) | 19/210 | 90.6 (54.5, 141.4) | <11 | 28.0 (10.3, 60.8) | <11 | 32.6 (13.1, 67.1) |
 Liposarcoma (n = 224) | 13/118 | 110.1 (58.6, 188.2) | <11 | 24.5 (5.1, 71.7) | <11 | 24.5 (5.0, 71.5) |
 MFH (n = 184) | 20/178 | 112.2 (68.5, 173.3) | <11 | 21.9 (6.0, 55.9) | <11 | 27.3 (8.9, 63.6) |
 Nerve sheath tumor (n = 118) | 15/93 | 160.8 (90.0, 265.3) | <11 | 40.7 (11.1, 104.2) | <11 | 49.8 (16.2, 116.3) |
 Sarcoma, NOS (n = 1,422) | 166/812 | 204.4 (174.5, 237.9) | 41/862 | 47.5 (34.1, 64.5) | 41/858 | 47.8 (34.3, 64.8) |
By history of VTEe | ||||||
 Yes | 61/51 | 1199.2 (917.3–1540.5) | 11/14 | 785.5 (392.3–1406.0) | 30/50 | 599.2 (404.3–855.4) |
 No | 306/2,417 | 126.6 (112.8–141.6) | 94/2,575 | 27.6 (24.3–31.1) | 76/2,540 | 29.9 (23.6–37.5) |
 Rate ratio (yes vs. no)d | – | 9.5 (7.2–12.5) | – | 21.5 (11.5–40.2) | – | 20.0 (13.1–30.6) |
By history of CVD eventf | ||||||
 Yes | 120/579 | 207.3 (171.9–247.9) | 29/623 | 46.6 (31.2–66.9) | 39/619 | 63.1 (44.8–86.2) |
 No | 247/1,889 | 130.8 (115.0–148.1) | 76/1,966 | 38.7 (30.5–48.4) | 67/1,971 | 34.0 (26.3–43.2) |
 Rate ratio (yes vs. no)d | – | 1.6 (1.3–2.0) |  | 1.2 (0.8–1.8) |  | 1.9 (1.3–2.8) |
By disease stage | ||||||
 Localized | 133/1,236 | 107.6 (90.1–127.5) | 38/1,290 | 29.5 (20.9–40.4) | 34/1,295 | 26.3 (18.2–36.7) |
 Regional | 93/586 | 158.7 (128.1–194.4) | 26/614 | 42.3 (27.7–62.1) | 34/610 | 55.7 (38.6–77.9) |
 Distant | 86/380 | 238.9 (191.1–295.0) | 25/385 | 65.0 (42.1–95.9) | 19/387 | 49.1 (29.6–76.7) |
 Rate ratio (regional and distant. vs. local)d | – | 1.5 (1.1–1.9) | – | 1.4 (0.9–2.4) | – | 2.1 (1.3–3.4) |
By chemotherapy | ||||||
 Yes | 74/324 | 227.9 (178.9–286.1) | 20/348 | 57.5 (35.1–88.7) | 19/346 | 54.9 (33.0–85.7) |
 No | 293/2,413 | 136.7 (121.5–153.3) | 85/2,241 | 37.9 (30.3–46.9) | 87/2,244 | 38.8 (31.1–47.8) |
 Rate ratio (yes vs. no)d | – | 1.7 (1.3–2.2) | – | 1.5 (0.9–2.5) |  | 1.4 (0.9–2.3) |
By surgery of primary tumor | ||||||
 Yes | 247/1,976 | 125.0 (109.9–141.6) | 72/2,065 | 34.9 (27.3–43.9) | 76/2,064 | 36.8 (29.0–46.1) |
 No | 115/467 | 246.4 (203.5–295.8) | 32/498 | 64.2 (43.9–90.7) | 29/501 | 57.9 (38.8–83.1) |
 Rate ratio (yes vs. no)d | – | 0.5 (0.4–0.6) | – | 0.5 (0.4–0.8) | – | 0.6 (0.4–1.0) |
By Primary site | ||||||
 Connective/subcutaneous | 136/830 | 163.9 (137.5–193.8) | 33/877 | 37.6 (25.9–52.8) | 37/875 | 42.3 (29.8–58.3) |
 Digestive system | 120/832 | 144.2 (119.5–172.4) | 38/879 | 43.2 (30.6–59.4) | 29/885 | 32.8 (22.0–47.1) |
 Other/unknowng | 111/805 | 137.8 (113.3–165.9) | 34/833 | 40.8 (28.3–57.0) | 40/830 | 48.2 (34.4–65.7) |